The most interesting aspect of Foundation Medicine (NASDAQ:FMI) is that, last year, cancer giant Roche (OTCQX:RHHBY) paid $50 per share to buy a 56% stake in the company. Bill Gates and Google (NASDAQ:GOOG) (NASDAQ:GOOGL) Ventures are also owners in this genomic testing company. However, right now, the stock is trading at $22.50, about half that Roche number.
Were all these smart people wrong? Did the M&A decision makers at Roche and the analysts working for Bill Gates and Google Ventures not do their homework? Or are we missing something here?